Implementing Genetics/ Genomic Medicine into Clinical Practice

Jessica Chong PA-C, MSHS

AAPA Annual Meeting May 22, 2024

Disclosures

 Non-Declaration Statement: I have no relevant relationships with ineligible companies to disclose within the past 24 months. (Note: Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.)


Educational Objectives

• Identify the characteristics of a patient's medical condition that may raise concerns for a possible genetic disease

 Outline what a PA can do to help streamline and enhance the efficacy of a genetics referral

 Encourage 'thinking genetics' when you might not have done before

Landmarks in genetics and genomics



1991

First US genome

1990

The Human Genome Project

(HGP) launched in

Ethical, legal and social implications (ELSI) programmes founded at the US National Institutes of Health (NIH) and Department of Energy (DOE)

First gene for

1992

human genetic map developed

Rapid-data-release quidelines established

by the NIH and DOE

The Sanger

(later rename

near Cami















US National Research Council issues report on Mapping and Sequencing the Human Genome STS Markers Sequence-tagged of yeast artificial sites (STS) mapping chromosome (YAC)

Human Genome **Proiect** concept established

The New York Times Magazine THE TECH AND DESIGN ISSUE




ILLUSTRATION BY BRIAN REA. ANIMATION BY DELCAN & COMPANY

FROM GENE EDITING TO A.I., HOW WILL TECHNOLOGY TRANSFORM HUMANITY?

FIVE BIG THINKERS — REGINA BARZILAY, GEORGE CHURCH, JENNIFER EGAN, CATHERINE MOHR AND SIDDHARTHA MUKHERJEE — PUZZLE OVER THE FUTURE OF THE FUTURE.

Bermuda principles for rapid and open data release established

Chinese National Human Genome Centers established in Beijing and Shanghai

Executive order bans genetic discrimination in US federal workplace



What are the challenges of implementation into clinical practice?

Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network


```
Nina R. Sperber, <sup>⊠1,7,16</sup> Janet S. Carpenter, <sup>2</sup> Larisa H. Cavallari, <sup>3</sup> Laura J. Damschroder, <sup>4</sup> Rhonda M. Cooper-DeHoff, <sup>5</sup> Joshua C. Denny, <sup>6</sup> Geoffrey S. Ginsburg, <sup>7</sup> Yue Guan, <sup>8</sup> Carol R. Horowitz, <sup>9</sup> Kenneth D. Levy, <sup>2</sup> Mia A. Levy, <sup>6</sup> Ebony B. Madden, <sup>10</sup> Michael E. Matheny, <sup>11</sup> Toni I. Pollin, <sup>8</sup> Victoria M. Pratt, <sup>2</sup> Marc Rosenman, <sup>2</sup> Corrine I. Voils, <sup>12,13</sup> Kristen W. Weitzel, <sup>5</sup> Russell A. Wilke, <sup>14</sup> R. Ryanne Wu, <sup>7,15</sup> and Lori A. Orlando <sup>7</sup>
```

- 1. Increase the relative priority of integrating genomics within the health system EHR
- 2. Strengthen clinicians' knowledge and beliefs about genomic medicine
- 3. Engage patients in the genomic medicine projects

Role of primary health care team

PCPs have a key role in identifying patients and families who may benefit from being referred for a genetic evaluation

PCPs are involved with managing, caring, and supporting families at risk for genetic conditions




HPI PEARLS

Birth history

- Prenatal and neonatal history
- Fetal movements
- Polyhydramnios or oligohydramnios
- Breech presentation or failure to progress
- Abnormal position to the hands/ feet, frogleg position, dislocated hips, scoliosis
- Respiratory and/ or feeding difficulties at birth

Family history

- Consanguinity and ethnicity ask EVERYONE!
- Death at an early age/ unknown reason
- Remote family members with similar symptoms
- Multiple miscarriages
- Anything weird



Early developmental milestones

- Don't believe "normal"
- Regression or plateau

Age of symptom onset

- Neonatal
- Congenital
- Childhood
- Adolescent
- Adult

Progression of symptoms

- Progressive, static, improving
- Acute vs.
 chronic


Other systemic involvement

- Cardiovascular
- Hepatomegaly
- Skeletal anomalies
- Arthrogryposis

PHYSICAL EXAM

Dysmorphic features

- Distinctive facial features
- Ear shape and position
- Eye spacing
- Body proportions and symmetry
- Spine or sacral anomalies
- Limbs/ digits
- Palmar creases





May involve taking measurements: height, weight, and head circumference – even in adults!



Note any change in findings over time



Depending on patient, specialized exam (neurological exam) may be performed



Angulo MA, 2015.



https://neuromuscular.wustl.edu/musdist/pe-eom.html







Bonnemann, CG, 2014.









Bodenseiner, JB, 2008.





Clayton-Smith, J, 2008.

Labs To Consider

- General investigation: CBC, CMP, vitamin D
- Low tone or weakness
 - Creatine Kinase (CK or CPK)
 - Thyroid function
 - Acute onset consider: toxins (heavy metals, drugs, botulism), infections (CBC, ESR)
- Metabolic
 - Lactate/ pyruvate, plasma amino acids, acylcarnitine profile, free/ total carnitine, urine organic acids
- Pain
 - CBC/ ferritin, CMP, Mg/ Phos
- Other
 - Fasting blood glucose, hemoglobin A1C, vitamin E/ B12

Case #1

Chief complaint: "Need note for school PE, walking funny"

History


- 10 yo boy with history of hypertrophic cardiomyopathy referred for gait disturbance
- Normal developmental history except mild speech delay
- Started walking "funny" starting 2 years ago
- Appears clumsy
- Younger siblings outrunning him
- Slurred speech

Work up

- Exam findings
 - +Dysarthria
 - Incoordinated limb movements
 - LE: Muscle atrophy and weakness
 - Bilateral ankle contractures and scoliosis
 - Sensory: Decreased vibration
 - Reflexes: 1+ in UE, absent in LE
 - Cerebellum: +Dysmetria (FTN), slow RAM, +nystagmus
 - Gait: Severely ataxic, difficulty with tandem and balance
 - +Romberg
- Labs:
 - Normal CBC, CMP, CK, TSH/ free T4, metabolic studies
- Prior genetic testing
 - Invitae hypertrophic cardiomyopathy panel negative

Friedreich's Ataxia

- Common form of inherited ataxia
- Autosomal recessive
- Affects approximately 1:40,000 live births with mean age of onset at 16 years
- Neurodegenerative disorder caused by mutations in frataxin (FTX) gene
- Primary involvement include CNS, spinal cord/ peripheral nerves, and heart



https://www.amboss.com/us/knowledge/friedreich-ataxia

Case #2

Chief complaint: "Falling a lot"


History

- 5 yo boy referred for progressive muscle weakness x 9-10 months
- Normal development except mild toe-walking
- Seems slower compared to peer group
- Frequent falling, fatigue
- Difficulty with climbing stairs

Work up


- Exam findings
 - Calf pseudohypertrophy, bilateral ankle contractures
 - Proximal muscle weakness
 - Waddling/ Trendelenburg gait and toe-walking
 - Difficulty walking up > down stairs
 - +Gowers Sign
- Labs
 - Elevated CK level = 30,000 (normal < 120)
 - AST and ALT elevated in 300's
- Pediatrician referred to gastroenterology
 - Normal hepatology work up, including liver biopsy
 - GI sent patient for neuromuscular evaluation

- Given history, physical exam findings, and CK elevation immediately sent for genetic testing
- Patient was found to have deletion of exons 48-50 (out of frame mutation) in the dystrophin gene




Duchenne Muscular Dystrophy

- X-linked recessive
- 1:5000 live male births most common form of muscular dystrophy
- Common symptoms:
 - Progressive proximal weakness, calf pseudohypertrophy, scoliosis, respiratory muscle weakness, cardiomyopathy
- Standards of care
- FDA approved disease modifying therapies



https://www.amboss.com/us/knowledge/progressive-muscular-dystrophies




https://takeonduchenne.eu/what-is-duchenne-muscular-dystrophy/

Dystrophin restoration: Exon-skipping

Strategy: Restore the reading frame of out-of-frame (ie, DMD) dystrophin transcripts to produce partially functional dystrophins (akin to BMD)

Different exons are skipped based on mutation size and location (mutation-specific)

Patient with DMD: Exon 48-50 out-of-frame 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 71 72 73 74 75 76 Out- of- frame mRNA DMD: No dystrophin



When do I refer to genetics?

Acute referral to clinic vs ER

Non-urgent referrals

Facilitate the referral – don't rely on the system!!!

In the meantime....

cgaggaaaggcgtatatgcggagt cgaggaaaggcgtatatgcggagt gagagcgctcttatcggcgatta gtgcggagtcgatgcgatcgg

aggegtatgegaggetagegtatgeta



Americans has a RARE DISEASE

30 million people have a serious, lifelong condition.

TTTT TTTT Holding hands, they would circle the globe about 1.5 times

More than half are children 1


What is a RARE DISEASE

Any disease, disorder, illness or condition affecting fewer than 200,000people in the United States is considered RARE.¹





Multidisciplinary Care





















References

- Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015 Dec;38(12):1249-63. doi: 10.1007/s40618-015-0312-9. Epub 2015 Jun 11. PMID: 26062517; PMCID: PMC4630255.
- Bodensteiner JB. The evaluation of the hypotonic infant. Semin Pediatr Neurol. 2008 Mar; 15(1):10-20. doi: 10.1016/j.spen.2008.01.003. PMID: 18342256.
- Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, Muntoni F, Sewry C, Béroud C, Mathews KD, Moore SA, Bellini J, Rutkowski A, North KN; Members of International Standard of Care Committee for Congenital Muscular Dystrophies. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014 Apr;24(4):289-311. doi: 10.1016/j.nmd.2013.12.011. Epub 2014 Jan 9. PMID: 24581957; PMCID: PMC5258110.
- Clayton-Smith, J. Assessment of the Dysmorphine Infant. Infant. 2008 Vol 4(6).
- Leyenaar J, Camfield P, Camfield C. A schematic approach to hypotonia in infancy. Paediatr Child Health. 2005 Sep;10(7):397-400. doi: 10.1093/pch/10.7.397. PMID: 19668647; PMCID: PMC2722561.
- Li Y, Bögershausen N, Alanay Y, Simsek Kiper PO, Plume N, Keupp K, Pohl E, Pawlik B, Rachwalski M, Milz E, Thoenes M, Albrecht B, Prott EC, Lehmkühler M, Demuth S, Utine GE, Boduroglu K, Frankenbusch K, Borck G, Gillessen-Kaesbach G, Yigit G, Wieczorek D, Wollnik B. A mutation screen in patients with Kabuki syndrome. Hum Genet. 2011 Dec;130(6):715-24. doi: 10.1007/s00439-011-1004-y. Epub 2011 May 24. PMID: 21607748.
- Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances. Int J MS Care. 2016 Nov-Dec;18(6):314-323. doi: 10.7224/1537-2073.2016-051. PMID: 27999526; PMCID: PMC5166599.
- Sperber NR, Carpenter JS, Cavallari LH, J Damschroder L, Cooper-DeHoff RM, Denny JC, Ginsburg GS, Guan Y, Horowitz CR, Levy KD, Levy MA, Madden EB, Matheny ME, Pollin TI, Pratt VM, Rosenman M, Voils CI, W Weitzel K, Wilke RA, Ryanne Wu R, Orlando LA. Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Med Genomics. 2017 May 22;10(1):35. doi: 10.1186/s12920-017-0273-2. PMID: 28532511; PMCID: PMC5441047.
- https://www.aafp.org/pubs/afp/issues/2005/0715/p279/icr:content/root/aafp-article-primary-content-container/aafp_article_main_par/aafp_figure.enlarge.html
- https://bioresource.nihr.ac.uk/centres-programmes/rare-diseases-bioresource/

